An end to the phenomenon of 'upgrading' in early prostate cancer? by Emberton, M
 1 
An end to the phenomenon of ‘up-grading’ in early prostate cancer? 
 
Mark Emberton FRCS (Urol) FMed Sci 
Division of Surgery and Interventional Science 
University College London 
m.emberton@ucl.ac.uk 
 
The phenomenon of ‘up-grading’ in early prostate cancer is one of those unusual 
events that is both useful to us on the one hand and at the same time undesirable on 
the other.  Useful - because the phenomenon gifts us a direct measure of the 
precision of our risk stratification methods for men recently diagnosed. Undesirable - 
because the perfect pathway should, ideally, be free of any ‘up-grading’.  
 
The phenomenon of ‘up-grading’ occurs in a number of settings.  We see it at play to 
some degree when an unreliable test is re-applied on the same subject.  The REDUCE 
study showed us that just under one fifth of men will convert from a status of 
‘cancer-free’ to one of ‘cancer-present’ as a result of a second exposure the same 
test – transrectal ultrasound (TRUS) guided biopsy (1).  We see it in full play when an 
unreliable test is followed by a more accurate test.  Shaw and colleagues – as have a 
number of others - reminded us once again of our limited ability to risk stratify 
patients with early prostate cancer.  They reported a 50% upgrading when they 
compared the results of TRUS biopsy against the final pathology at radical 
prostatectomy.  In other words, half the patients went on to their definitive therapy 
with an incorrect grade attribution (2).   
 
It would be a great pity if, in the modern era, the only route available to patients 
who wanted to be sure of their risk status was to agree to surgical removal of the 
prostate.  Surely, the value of accurate risk stratification is derived from using it to 
allocate appropriate and effective care.  Risk stratification needs to be linked to or 
closely follow diagnosis if it is to be put to work for patients.  
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Nowhere is this need greater than in men whose treatment preference is tissue 
preservation.  The study, in this issue, by Pessoa and colleagues adds to our 
knowledge on the subject and equips us with a strategy to mitigate some of the 
errors that are inherent to the standard diagnostic pathway (3).  
 
In this study, the authors evaluated the role of a single exposure to MRI (and the 
opportunity that resulted to undertake a targeted biopsy to an MRI-derived 
abnormality as well as systematic sampling) to 105 men who had been attributed a 
diagnosis of low risk prostate cancer – and, as a result, were deemed to be suitable 
for active surveillance. The authors used the PIRADS system to interpret and 
communicate MRI-risk.  In summary, men attributed a low PIRADS score (PIRADS 1-
3) had a low probability of being re-classified to a higher risk.  In contrast, men 
attributed PIRADS 4 or 5 had between a 70-100% of being re-classified.  The authors 
calculated a sensitivity of 93% for MRI to predict ‘re-classification’.  This equates to a 
93% sensitivity to predict the presence of clinically significant disease as re-
classification occurred when there was a transition from low risk to higher risk 
disease.  
 
These results concur with those of others that are working in this area (4) and are in 
line with current recommendations (5).   One observation that is worth highlighting – 
because it is a current controversy in the field - relates to the utility of the systematic 
(or semi-random) biopsies as a component of the confirmatory biopsy.  Whilst 
targeted biopsy was superior to systematic biopsy at identifying clinically significant 
disease, omission of the systematic biopsies would have resulted in 5 significant 
cancers being overlooked.   The less perfect the targeted biopsy, the greater the 
reliance on the systematic.  In this study, the lesion-generation and the targeting 
may have been compromised by one or two issues.  Using TRUS biopsy as the 
authors did (as opposed to trans-perineal biopsy) to access all areas of the prostate 
is always going to be a challenge.  To do so without image-registration makes it even 
harder.  To use PIRADS – as opposed to a Likert scale - as a method of interpreting 
and communicating MRI outputs will, very likely, lead to an under-reporting of the 
smaller, high-grade lesions (6). This is because PIRADS 2.0 is triggered by a volume 
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threshold towards the upper end of the scale.  Such lesions might be more prevalent 
in an apparently ‘low-risk’ population such as the one under scrutiny.  If this is the 
case, they will not be identified as ‘targets’ by virtue of a high PIRADS score.  As a 
consequence they cannot be identified by targeting but might be picked up by the 
random fall of the needles.  
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